Literature DB >> 25691085

Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy.

Sausan Abouharb1, Stacy Moulder.   

Abstract

Metaplastic breast cancer is a rare subtype of invasive mammary carcinoma, with an aggressive behavior and usually poor outcome. Responses to systemic chemotherapy are suboptimal compared to patients with standard invasive ductal carcinoma. Limited data are available in regards to best treatment modalities, including chemotherapy. This review gives an overview of metaplastic breast cancer and its clinical and pathologic characteristics, in addition to treatment strategies, clinical trials, and future directions.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25691085     DOI： 10.1007/s11912-014-0431-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  55 in total

1.  Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells.

Authors:  E S Wargotz; H J Norris
Journal:  Hum Pathol       Date:  1990-11       Impact factor: 3.466

2.  Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer.

Authors:  So-Youn Jung; Hyun Yul Kim; Byung-Ho Nam; Sun Young Min; Seung Ju Lee; Chansung Park; Youngmee Kwon; Eun-A Kim; Kyoung Lan Ko; Kyung Hwan Shin; Keun Seok Lee; In Hae Park; Seeyoun Lee; Seok Won Kim; Han-Sung Kang; Jungsil Ro
Journal:  Breast Cancer Res Treat       Date:  2010-02-09       Impact factor: 4.872

3.  Metaplastic carcinomas of the breast. II. Spindle cell carcinoma.

Authors:  E S Wargotz; P H Deos; H J Norris
Journal:  Hum Pathol       Date:  1989-08       Impact factor: 3.466

4.  Metaplastic carcinoma of the breast: a retrospective review.

Authors:  Giatri Dave; Harry Cosmatos; Tri Do; Kenneth Lodin; Dolly Varshney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-24       Impact factor: 7.038

5.  Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin.

Authors:  E S Wargotz; H J Norris
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

6.  Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.

Authors:  J A Jacobson; D N Danforth; K H Cowan; T d'Angelo; S M Steinberg; L Pierce; M E Lippman; A S Lichter; E Glatstein; P Okunieff
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

Review 7.  Current progress in the treatment of metaplastic breast carcinoma.

Authors:  Qing Hu; Wei-Xian Chen; Shan-Liang Zhong; Jian Li; Zhou Luo; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Asian Pac J Cancer Prev       Date:  2013

8.  The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.

Authors:  Hung-Wen Lai; Ling-Ming Tseng; Tsai-Wang Chang; Yao-Lung Kuo; Chia-Ming Hsieh; Shou-Tung Chen; Sou-Jen Kuo; Chin-Cheng Su; Dar-Ren Chen
Journal:  Breast       Date:  2013-06-17       Impact factor: 4.380

9.  Review of metaplastic carcinoma of the breast: imaging findings and pathologic features.

Authors:  Rebecca Leddy; Abid Irshad; Tihana Rumboldt; Abbie Cluver; Amy Campbell; Susan Ackerman
Journal:  J Clin Imaging Sci       Date:  2012-04-28

10.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583
View more
  18 in total

1.  Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database.

Authors:  Cecilia T Ong; Brittany M Campbell; Samantha M Thomas; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Jeremy Force; Allison Hall; Terry Hyslop; E Shelley Hwang; Oluwadamilola M Fayanju
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

2.  Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Authors:  Reva K Basho; Clinton Yam; Michael Gilcrease; Rashmi K Murthy; Thorunn Helgason; Daniel D Karp; Funda Meric-Bernstam; Kenneth R Hess; Vicente Valero; Constance Albarracin; Jennifer K Litton; Mariana Chavez-MacGregor; David Hong; Razelle Kurzrock; Gabriel N Hortobagyi; Filip Janku; Stacy L Moulder
Journal:  Oncologist       Date:  2018-08-23

3.  Higher efficacy and complete response with administration of eribulin for recurrent squamous cell breast carcinoma: A case report.

Authors:  Yoshinari Goto; Takashi Yoshida; Morihiko Kimura
Journal:  Mol Clin Oncol       Date:  2018-07-19

4.  Combined Use of Mammography and FNA Eliminates Pitfalls in the Management of Metaplastic Breast Carcinoma.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Schizas; Anargyros Bakopoulos; Demetrios Moris; Gabriela-Monica Stanc; Anastasios Tentolouris; Soumphi Nassar; Charitini Salla
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 5.  Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas.

Authors:  Mai N Tran; Celina G Kleer
Journal:  J Cell Commun Signal       Date:  2018-01-22       Impact factor: 5.782

Review 6.  Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.

Authors:  Clinton Yam; Sendurai A Mani; Stacy L Moulder
Journal:  Oncologist       Date:  2017-05-30

7.  Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.

Authors:  Clinton Yam; Nour Abuhadra; Ryan Sun; Beatriz E Adrada; Qing-Qing Ding; Jason B White; Elizabeth E Ravenberg; Alyson R Clayborn; Vicente Valero; Debu Tripathy; Senthilkumar Damodaran; Banu K Arun; Jennifer K Litton; Naoto T Ueno; Rashmi K Murthy; Bora Lim; Luis Baez; Xiaoxian Li; Aman U Buzdar; Gabriel N Hortobagyi; Alistair M Thompson; Elizabeth A Mittendorf; Gaiane M Rauch; Rosalind P Candelaria; Lei Huo; Stacy L Moulder; Jeffrey T Chang
Journal:  Clin Cancer Res       Date:  2022-07-01       Impact factor: 13.801

8.  Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.

Authors:  Mary C Schroeder; Priya Rastogi; Charles E Geyer; Lance D Miller; Alexandra Thomas
Journal:  Oncologist       Date:  2018-01-12

9.  Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.

Authors:  Elan Gorshein; Kant Matsuda; Gregory Riedlinger; Levi Sokol; Lorna Rodriguez-Rodriguez; Firas Eladoumikdachi; Miral Grandhi; Shridar Ganesan; Deborah L Toppmeyer; Lindsay Potdevin; Kathleen Toomey; Kim M Hirshfield; Nancy Chan
Journal:  Case Rep Oncol       Date:  2021-06-18

10.  PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.

Authors:  Anne Grabenstetter; Achim A Jungbluth; Denise Frosina; Raza Hoda; Carlos H Dos Anjos; Sujata Patil; Varadan Sevilimedu; Britta Weigelt; Jorge S Reis-Filho; Hong Zhang; Tiffany Traina; Mark E Robson; Edi Brogi; Hannah Y Wen
Journal:  Am J Surg Pathol       Date:  2021-09-01       Impact factor: 6.298
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.